| Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes |
146 |
| Drug resistance and new therapies in colorectal cancer |
61 |
| Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis |
56 |
| Biomarkers of gastric cancer: Current topics and future perspective |
46 |
| Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation |
42 |
| Challenges in diagnosis of pancreatic cancer |
41 |
| Recent advances in gastric cancer early diagnosis |
41 |
| Predictive factors for anastomotic leakage after laparoscopic colorectal surgery |
40 |
| Apoptosis and non-alcoholic fatty liver diseases |
38 |
| Current global trends in the incidence of pediatric-onset inflammatory bowel disease |
36 |
| Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma |
36 |
| Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond |
34 |
| Beneficial effects of naringenin in liver diseases: Molecular mechanisms |
33 |
| Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From two hit theory to multiple hit model |
32 |
| Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer |
30 |
| Role of diet and gut microbiota on colorectal cancer immunomodulation |
30 |
| Helicobacter pylori and extragastric diseases: A review |
29 |
| Iron and liver fibrosis: Mechanistic and clinical aspects |
29 |
| Systematic review of colorectal cancer screening guidelines for average-risk adults: Summarizing the current global recommendations |
28 |
| Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma |
28 |
| Long noncoding RNA RP4 functions as a competing endogenous RNA through miR-7-5p sponge activity in colorectal cancer |
28 |
| From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting |
28 |
| MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside |
27 |
| Current clinical management of gastrointestinal stromal tumor |
26 |
| Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? |
26 |
| Hepatocellular carcinoma surveillance: An evidence-based approach |
26 |
| Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified |
25 |
| Mechanisms of hepatocellular carcinoma progression |
25 |
| Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? |
25 |
| Mediterranean diet and nonalcoholic fatty liver disease |
25 |
| MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: Current insights and future perspectives |
25 |
| Microbiota modification by probiotic supplementation reduces colitis associated colon cancer in mice |
24 |
| Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma |
24 |
| Current status, problems, and perspectives of non-alcoholic fatty liver disease research |
24 |
| Immunotherapy for hepatocellular carcinoma: Current and future |
23 |
| Liver transplantation and alcoholic liver disease: History, controversies, and considerations |
23 |
| Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations |
22 |
| CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer |
22 |
| Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice |
22 |
| Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art |
21 |
| Application of artificial intelligence in gastroenterology |
21 |
| Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment |
20 |
| Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer |
20 |
| International consensus statement on robotic hepatectomy surgery in 2018 |
20 |
| Helicobacter pylori in human health and disease: Mechanisms for local gastric and systemic effects |
20 |
| impact of mechanical bowel preparation in elective colorectal surgery: a meta-analysis |
20 |
| Impact of enhanced recovery after surgery programs on pancreatic surgery: A meta-analysis |
19 |
| Pediatric hepatocellular carcinoma |
19 |
| Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? |
19 |
| Role of ion channels in gastrointestinal cancer |
18 |
